Phase 1 study of anti-PD-L1 durvalumab plus gefitinib in TKI-naïve patients with EGFR-mutant NSCLC

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Don Gibbons, MD, PhD, from The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a phase 1 expansion study evaluating the efficacy, safety and tolerability of durvalumab, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib for tyrosine kinase inhibitor-naïve patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC).
Share this video